Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer
ConclusionRadiomics signature may be an independent imaging biomarker for predicting the survival, which may guide for personalizing treatment option in patients with stage I NSCLC.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | Study